Megan E H Still, Rachel S F Moor, Ashley P Ghiaseddin, Annette Leibetseder, Andreas F Hottinger, Anna Berghoff, Denise Leung
{"title":"如何在idh突变型胶质瘤患者中开具和管理mIDH抑制剂？","authors":"Megan E H Still, Rachel S F Moor, Ashley P Ghiaseddin, Annette Leibetseder, Andreas F Hottinger, Anna Berghoff, Denise Leung","doi":"10.1093/nop/npae112","DOIUrl":null,"url":null,"abstract":"<p><p>Recent interest has been in using mIDH inhibitors in patients with IDH-mutant gliomas. This review paper summarizes the indications, side effects, recommended dosing, and management for patients on ivosidenib and vorasidenib.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 Suppl 1","pages":"i19-i25"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703362/pdf/","citationCount":"0","resultStr":"{\"title\":\"How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma?\",\"authors\":\"Megan E H Still, Rachel S F Moor, Ashley P Ghiaseddin, Annette Leibetseder, Andreas F Hottinger, Anna Berghoff, Denise Leung\",\"doi\":\"10.1093/nop/npae112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Recent interest has been in using mIDH inhibitors in patients with IDH-mutant gliomas. This review paper summarizes the indications, side effects, recommended dosing, and management for patients on ivosidenib and vorasidenib.</p>\",\"PeriodicalId\":19234,\"journal\":{\"name\":\"Neuro-oncology practice\",\"volume\":\"12 Suppl 1\",\"pages\":\"i19-i25\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-12-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703362/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/nop/npae112\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npae112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma?
Recent interest has been in using mIDH inhibitors in patients with IDH-mutant gliomas. This review paper summarizes the indications, side effects, recommended dosing, and management for patients on ivosidenib and vorasidenib.
期刊介绍：
Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
